AZN

AstraZeneca PLC American Depositary Shares (AZN) | Rumor.io

AstraZeneca

AZN

Attention (50-day avg)0%

Attention rank (50-day avg)#679

Bullish sentiment (50-day avg)67%

Price to earnings ratio24.8

Market capitalization257.7B

Earnings per share6.73

Dividend yield (TTM)2.59%

Revenue (annual)58.7B

Net income (annual)10.2B

Social

What share of all stock conversation is about AZN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0.01% +0	0% -0.01	0.01% -0.01

Sep 29

AstraZeneca has invested $2 billion in Summit Therapeutics, with the deal price being $18.36 per share, representing an 18.6% increase over Monday's close.
The investment is part of a collaboration between the two companies to accelerate the development of Ivonescimab, a cancer drug, and to evaluate its combination with other AstraZeneca cancer medicines.
Summit Therapeutics' stock price has risen by 23% in premarket trading, with analysts predicting a possible price of $20 in the short term, pending the outcome of clinical trials and regulatory milestones.

Generated by AI

Sentiment

Of the messages about AZN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	95.24%	95.35% -4.65	78.35% +53.3	78.6% -7.21
Bearish	4.76%	4.65% new	21.65% -53.3	21.4% +7.21

Bullish· Aug 3

A potential combination of AstraZeneca and Bristol Myers Squibb could create the world's largest drugmaker, worth nearly $400 billion, and drive significant growth through oncology, rare disease, and cardiovascular therapies.
AstraZeneca has been one of the pharmaceutical industry's great comeback stories, with strong delivery of growth through its global pipeline and potential for further growth through a merger with Bristol Myers Squibb.
Analysts at TD Cowen estimate that an AstraZeneca-Bristol Myers Squibb merger could result in a 25% increase in average price target to $213.69, driven by synergies and boosted EPS growth.

Bearish· Aug 3

AstraZeneca's stock price has fallen to levels not seen in 3 years, with an RSI of 27, and a merger that may not materialize.
The proposed merger with Bristol Myers Squibb is being seen as a negative development, with investors balking at reports of the talks.
The potential merger with Bristol Myers Squibb may lead to a financing burden, possible dilution, and integration risks for AstraZeneca shareholders before any transaction structure or economic benefits are known.

Generated by AI

Topics

Of the messages about AZN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	61.33%	69.79%	71.82%	34.14%
Analysts	20%	15.63%	11.11%	17.77%
Technical Analysis	0%	0%	1.03%	1.34%
Macro	18.67%	14.58%	9.51%	41.99%
Earnings	0%	0%	6.41%	3.7%
Controversies	0%	0%	0.11%	1.05%

Earnings· Jul 27

AstraZeneca reported Q2 2026 earnings with core EPS of $2.63, a 21% increase and a beat of $2.48 consensus.
The company reiterated its guidance of $80 billion for 2030, a 33% increase from 2026.
AstraZeneca's revenue for Q2 2026 was $15.38B, a 6% Y/Y increase, and core EPS growth outpaced revenue growth, 3:1.

Analysts· Sep 25

AstraZeneca (AZN) was upgraded to Buy from Hold at Jefferies, with a price target of $80.
Analyst Peter Welford from Jefferies upgraded AZN to Buy, citing overlooked opportunities in the company's pipeline.
The analyst consensus for AZN has changed from Moderate Buy to Strong Buy, according to Tip Ranks.

Announcements· Sep 29

AstraZeneca (AZN) has invested $2B in Summit Therapeutics (SMMT) to accelerate the development of Ivonescimab, a cancer drug, and will collaborate on its development.
The deal is seen as a "de-risking event" that removes Summit's financing overhang, with Citi raising its price target on Summit to $43 from $40.
AstraZeneca and Summit will also collaborate on a clinical trial to evaluate Ivonescimab in combination with other cancer medicines, including Sonesitatug Vedotin in multiple gastrointestinal cancers.

Controversies· May 10

AstraZeneca PLC's vaccine was heavily criticized in Germany, with the health minister denying a connection between the vaccine and blood clots.
This denial of side effects led some individuals to become skeptical about the vaccine, despite initially being in favor of it.
The controversy surrounding AstraZeneca's vaccine has sparked concerns about its safety and efficacy.

Macro· Jul 20

The success of AstraZeneca's vaccine, developed in partnership with Oxford, may be influenced by funding and distribution agreements, potentially giving AstraZeneca control over manufacturing and distribution.
A vaccine, particularly one from AstraZeneca, is crucial for addressing the COVID-19 pandemic, and its deployment could be a key factor in the US election and global economic recovery.
Emerging data suggest that a T-cell response, rather than antibody production, may be a key factor in mitigating COVID-19, and AstraZeneca's vaccine may induce such a response.

Technical Analysis· Jul 23

AZN has entered oversold territory on the hourly RSI, suggesting a potential correction tomorrow and into next week.
The stock is bouncing off the 20-day moving average and may add to its position here.
AZN is expected to bounce at $53, with some analysts suggesting it may be a good time to load up on the stock.

Generated by AI

Community

Of the messages about AZN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	74.06%	62.07%	57%	48.77%
Newcomers	25.94%	37.93%	43%	51.23%

Regulars· Sep 29

AstraZeneca is investing $2 billion in Summit Therapeutics, with the deal including a 10% stake in Summit and the right to convert the investment into shares at a price of $18.36 per common share.
Summit Therapeutics' price target has been raised to $43 from $40 at Citi, following the investment announcement, and the company's shares have risen by 19.6% pre-market.
AstraZeneca and Summit Therapeutics plan to collaborate on cancer drug development, with a clinical trial collaboration to evaluate Ivonescimab in combination with Sonesitatug Vedotin in multiple gastrointestinal cancers.

Newcomers· Sep 8

AstraZeneca's COPD drug, tozorakimab, has shown positive results in two late-stage trials, reducing moderate and severe exacerbations by 29-34%.
AstraZeneca's Imfinzi and Imdelltra combination has met the Phase 3 overall survival goals in extensive-stage small cell lung cancer.
AstraZeneca's tozorakimab has been approved by the FDA for the treatment of HR+ breast cancer, with a 56% risk reduction in PFS.

Generated by AI

News

Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal

2h agoInvesting.com

Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note

Astrazeneca (AZN) closed at $164.21 in the latest trading session, marking a -1.17% move from the prior day.

15h agosg.finance.yahoo.com

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

The companies will start by testing ivonescimab with an AstraZeneca ADC in gastrointestinal cancers

20h agoYahoo Finance

Also Discussed

Investors talking about AZN also mention

#	Name	Attention
1	Pfizer Inc.PFE	0.04%-0.01
2	Novartis AG Sponsored ADRNVS	0%-0.01
3	Sanofi ADRSNY	0%-0.01
4	Merck & Co., Inc.MRK	0.01%-0.06
5	Bristol-Myers Squibb CompanyBMY	0.01%0
6	BioNTech SEBNTX	0%+0
7	GSK plc ADRGSK	0%0
8	Amgen Inc.AMGN	0.01%+0
9	Moderna Inc.MRNA	0.1%+0.03
10	Gilead Sciences, Inc.GILD	0%-0.04

AstraZeneca PLC American Depositary Shares

Healthcare
Drug Manufacturers - General

AstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. AstraZeneca’s current business spans Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company develops and markets treatments used across hospitals, clinics, and specialty care settings, serving patients and healthcare providers in major therapeutic areas with high unmet medical need. Its portfolio is built around branded medicines and regulated drug launches, with ongoing commercial activity across the United States, Europe, and other international markets. AstraZeneca PLC American Depositary Shares provide U.S. investors a way to hold an instrument linked to the company’s underlying shares while participating in the performance of one of the world’s largest research-driven drugmakers.

Website

Location

1 Francis Crick Avenue

Cambridge, CB2 0AA

United Kingdom

Social

What share of all stock conversation is about AZN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0.01% +0	0% -0.01	0.01% -0.01

Sep 29

AstraZeneca has invested $2 billion in Summit Therapeutics, with the deal price being $18.36 per share, representing an 18.6% increase over Monday's close.
The investment is part of a collaboration between the two companies to accelerate the development of Ivonescimab, a cancer drug, and to evaluate its combination with other AstraZeneca cancer medicines.
Summit Therapeutics' stock price has risen by 23% in premarket trading, with analysts predicting a possible price of $20 in the short term, pending the outcome of clinical trials and regulatory milestones.

Generated by AI

Sentiment

Of the messages about AZN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	95.24%	95.35% -4.65	78.35% +53.3	78.6% -7.21
Bearish	4.76%	4.65% new	21.65% -53.3	21.4% +7.21

Bullish· Aug 3

A potential combination of AstraZeneca and Bristol Myers Squibb could create the world's largest drugmaker, worth nearly $400 billion, and drive significant growth through oncology, rare disease, and cardiovascular therapies.
AstraZeneca has been one of the pharmaceutical industry's great comeback stories, with strong delivery of growth through its global pipeline and potential for further growth through a merger with Bristol Myers Squibb.
Analysts at TD Cowen estimate that an AstraZeneca-Bristol Myers Squibb merger could result in a 25% increase in average price target to $213.69, driven by synergies and boosted EPS growth.

Bearish· Aug 3

AstraZeneca's stock price has fallen to levels not seen in 3 years, with an RSI of 27, and a merger that may not materialize.
The proposed merger with Bristol Myers Squibb is being seen as a negative development, with investors balking at reports of the talks.
The potential merger with Bristol Myers Squibb may lead to a financing burden, possible dilution, and integration risks for AstraZeneca shareholders before any transaction structure or economic benefits are known.

Generated by AI

Topics

Of the messages about AZN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	61.33%	69.79%	71.82%	34.14%
Analysts	20%	15.63%	11.11%	17.77%
Technical Analysis	0%	0%	1.03%	1.34%
Macro	18.67%	14.58%	9.51%	41.99%
Earnings	0%	0%	6.41%	3.7%
Controversies	0%	0%	0.11%	1.05%

Earnings· Jul 27

AstraZeneca reported Q2 2026 earnings with core EPS of $2.63, a 21% increase and a beat of $2.48 consensus.
The company reiterated its guidance of $80 billion for 2030, a 33% increase from 2026.
AstraZeneca's revenue for Q2 2026 was $15.38B, a 6% Y/Y increase, and core EPS growth outpaced revenue growth, 3:1.

Analysts· Sep 25

AstraZeneca (AZN) was upgraded to Buy from Hold at Jefferies, with a price target of $80.
Analyst Peter Welford from Jefferies upgraded AZN to Buy, citing overlooked opportunities in the company's pipeline.
The analyst consensus for AZN has changed from Moderate Buy to Strong Buy, according to Tip Ranks.

Announcements· Sep 29

AstraZeneca (AZN) has invested $2B in Summit Therapeutics (SMMT) to accelerate the development of Ivonescimab, a cancer drug, and will collaborate on its development.
The deal is seen as a "de-risking event" that removes Summit's financing overhang, with Citi raising its price target on Summit to $43 from $40.
AstraZeneca and Summit will also collaborate on a clinical trial to evaluate Ivonescimab in combination with other cancer medicines, including Sonesitatug Vedotin in multiple gastrointestinal cancers.

Controversies· May 10

AstraZeneca PLC's vaccine was heavily criticized in Germany, with the health minister denying a connection between the vaccine and blood clots.
This denial of side effects led some individuals to become skeptical about the vaccine, despite initially being in favor of it.
The controversy surrounding AstraZeneca's vaccine has sparked concerns about its safety and efficacy.

Macro· Jul 20

The success of AstraZeneca's vaccine, developed in partnership with Oxford, may be influenced by funding and distribution agreements, potentially giving AstraZeneca control over manufacturing and distribution.
A vaccine, particularly one from AstraZeneca, is crucial for addressing the COVID-19 pandemic, and its deployment could be a key factor in the US election and global economic recovery.
Emerging data suggest that a T-cell response, rather than antibody production, may be a key factor in mitigating COVID-19, and AstraZeneca's vaccine may induce such a response.

Technical Analysis· Jul 23

AZN has entered oversold territory on the hourly RSI, suggesting a potential correction tomorrow and into next week.
The stock is bouncing off the 20-day moving average and may add to its position here.
AZN is expected to bounce at $53, with some analysts suggesting it may be a good time to load up on the stock.

Generated by AI

Community

Of the messages about AZN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	74.06%	62.07%	57%	48.77%
Newcomers	25.94%	37.93%	43%	51.23%

Regulars· Sep 29

AstraZeneca is investing $2 billion in Summit Therapeutics, with the deal including a 10% stake in Summit and the right to convert the investment into shares at a price of $18.36 per common share.
Summit Therapeutics' price target has been raised to $43 from $40 at Citi, following the investment announcement, and the company's shares have risen by 19.6% pre-market.
AstraZeneca and Summit Therapeutics plan to collaborate on cancer drug development, with a clinical trial collaboration to evaluate Ivonescimab in combination with Sonesitatug Vedotin in multiple gastrointestinal cancers.

Newcomers· Sep 8

AstraZeneca's COPD drug, tozorakimab, has shown positive results in two late-stage trials, reducing moderate and severe exacerbations by 29-34%.
AstraZeneca's Imfinzi and Imdelltra combination has met the Phase 3 overall survival goals in extensive-stage small cell lung cancer.
AstraZeneca's tozorakimab has been approved by the FDA for the treatment of HR+ breast cancer, with a 56% risk reduction in PFS.

Generated by AI

AstraZeneca

Social

Sep 29

Bullish· Aug 3

Bearish· Aug 3

Earnings· Jul 27

Analysts· Sep 25

Announcements· Sep 29

Controversies· May 10

Macro· Jul 20

Technical Analysis· Jul 23

Regulars· Sep 29

Newcomers· Sep 8

Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal

Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC

AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

Also Discussed

AstraZeneca PLC American Depositary Shares

Company Information

Location

Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal

Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC

AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

Also Discussed

Social

Sep 29

Bullish· Aug 3

Bearish· Aug 3

Earnings· Jul 27

Analysts· Sep 25

Announcements· Sep 29

Controversies· May 10

Macro· Jul 20

Technical Analysis· Jul 23

Regulars· Sep 29

Newcomers· Sep 8